Bristol-Myers Squibb Company (NYSE:BMY) – Stock analysts at SunTrust Banks raised their Q3 2017 EPS estimates for shares of Bristol-Myers Squibb in a report issued on Monday. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will post earnings per share of $0.77 for the quarter, up from their previous estimate of $0.70. SunTrust Banks also issued estimates for Bristol-Myers Squibb’s Q4 2017 earnings at $0.65 EPS, FY2020 earnings at $4.08 EPS and FY2021 earnings at $4.28 EPS.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. Bristol-Myers Squibb’s quarterly revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the business posted $0.69 earnings per share.
COPYRIGHT VIOLATION WARNING: “Q3 2017 Earnings Forecast for Bristol-Myers Squibb Company Issued By SunTrust Banks (BMY)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/q3-2017-earnings-forecast-for-bristol-myers-squibb-company-issued-by-suntrust-banks-bmy.html.
Several other research firms also recently weighed in on BMY. Cowen and Company restated a “hold” rating and set a $65.00 target price on shares of Bristol-Myers Squibb in a report on Tuesday, September 19th. Jefferies Group LLC raised their target price on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a report on Monday, September 11th. Vetr downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 target price for the company. in a report on Thursday, September 28th. UBS AG restated a “buy” rating and set a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 target price for the company. in a report on Tuesday, September 12th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $63.79.
Bristol-Myers Squibb (NYSE:BMY) opened at 63.70 on Wednesday. The company’s 50-day moving average is $63.11 and its 200-day moving average is $57.16. Bristol-Myers Squibb has a 52-week low of $46.01 and a 52-week high of $66.10. The firm has a market capitalization of $104.46 billion, a price-to-earnings ratio of 23.27 and a beta of 1.19.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Stillwater Investment Management LLC acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth approximately $202,000. Beacon Financial Group boosted its position in shares of Bristol-Myers Squibb by 1.6% in the third quarter. Beacon Financial Group now owns 96,488 shares of the biopharmaceutical company’s stock worth $3,985,000 after acquiring an additional 1,541 shares during the last quarter. McQueen Ball & Associates Inc. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth approximately $214,000. Curbstone Financial Management Corp boosted its position in shares of Bristol-Myers Squibb by 103.3% in the third quarter. Curbstone Financial Management Corp now owns 12,814 shares of the biopharmaceutical company’s stock worth $817,000 after acquiring an additional 6,510 shares during the last quarter. Finally, Bridges Investment Management Inc. boosted its position in shares of Bristol-Myers Squibb by 8.7% in the third quarter. Bridges Investment Management Inc. now owns 14,214 shares of the biopharmaceutical company’s stock worth $906,000 after acquiring an additional 1,143 shares during the last quarter. 68.84% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Theodore R. Samuels II bought 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 2nd. The shares were acquired at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Joseph C. Caldarella sold 9,340 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by company insiders.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be given a $0.39 dividend. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.45%. Bristol-Myers Squibb’s dividend payout ratio is presently 56.73%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.